Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The HER-2/neu oncogene in tumors of the gastrointestinal tract.

Cancer investigation - 1 Jan 2001

Ross J S, McKenna B J

Abstract excerpt

The HER-2/neu oncogene is localized to chromosome 17q and shares significant homology with the epidermal growth factor receptor. As a result of its potential role in the selection of therapy, HER-2/neu testing has reached near-standard-of-practice status in breast cancer. There is considerable interest in HER-2/neu as a prognostic factor and target of therapy in tumors of the gastrointestinal tract. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Squamous Cell
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Esophageal Neoplasms

Share to Gastrointestinal Neoplasms

Share to Genes, erbB-2

Share to In Situ Hybridization, Fluorescence

Share to Stomach Neoplasms

Source

Identifiers

PMID: 11458821
DOI: 10.1081/cnv-100103852

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The HER-2/neu oncogene in tumors of the gastrointestinal tract.PMID 11458821Read ↗

Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.Semantic proximity Read ↗

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.Semantic proximity Read ↗

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.Semantic proximity Read ↗

Clinical impact of tumour biology in the management of gastroesophageal cancer.Semantic proximity Read ↗

Targeting HER2 expression in cancer: New drugs and new indications.Semantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene.Semantic proximity Read ↗

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trialSemantic proximity Read ↗

Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor OutcomeSemantic proximity Read ↗

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.Semantic proximity Read ↗

Targeting the function of the HER2 oncogene in human cancer therapeuticsSemantic proximity Read ↗

HER‐2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.